CONFERENCEEUCAIM
EUCAIM – European Federation for Cancer Images
Project Description
EUCAIM (European Federation for Cancer Images) is a flagship initiative of the European Union’s Europe’s Beating Cancer Plan, bringing together 95 partners from 17 countries. The project aims to build a pan-European federated digital infrastructure providing secure access to de-identified cancer images and related clinical data, in line with the FAIR principles (Findable, Accessible, and Interoperable, Re-usable).
The project builds on the results and repositories of the five EU projects of the AI4HI network (CHAIMELEON, EUCANIMAGE, INCISIVE, ProCancer-I, PRIMAGE), and involves major European research infrastructures such as Euro-BioImaging, BBMRI, EATRIS, and ELIXIR.
Its key outcome will be the European Cancer Image Atlas – a central resource for clinicians, researchers, innovators, and policymakers. The Atlas will provide comprehensive, high-quality datasets to develop and validate AI solutions for personalised medicine. The platform will support federated search, annotation, metadata aggregation, and distributed processing, including privacy-preserving federated machine learning.
EUCAIM also develops the legal and organizational framework for cross-border data use across Europe, aligned with the future European Health Data Space (EHDS).
Project Objectives:
• Establish a federated European cancer imaging infrastructure and data atlas;
• Integrate multimodal clinical, pathology, molecular, and laboratory data;
• Provide secure and privacy-preserving tools for AI development and validation;
• Develop the legal and organizational framework for data use in line with the EHDS;
• Ensure a sustainable and widely accessible resource for clinicians, researchers, industry, and policymakers.
Duration: 01.01.2023 – 31.12.2026
Latvia joined the consortium on 1 January 2025.
Project number: ID No. 101100633, UL registration No. ZD2025/21882
UL total funding: EUR 213,712.68
Programme: Digital Europe Programme
Coordinator: EIBIR GEMEINNÜTZIGE GMBH (Austria)
Consortium: 95 partner organisations from 17 countries, including universities, hospitals, research institutes, industry partners, and patient organisations.
Project Partners
BBMRI-ERIC, European Institute for Biomedical Imaging Research (EIBIR), Medical University of Innsbruck, Medical University of Vienna, COCIR, KU Leuven, Radiomics, Sciensano, German Oncology Center, Masaryk University, Better Medicine OU, Euro-BioImaging ERIC, Wellbeing Services County of North Savo, Assistance Publique Hôpitaux de Paris, CNRS, Collège des Enseignants en Radiologie de France, INRIA – French Institute for Research in Computer Science and Automation, LIMICS, Medexprim, GE HealthCare, Charité Universitätsmedizin Berlin, ELIXIR, German Cancer Research Center (DKFZ), Deutsches Elektronen-Synchrotron (DESY), Philips GmbH, Technical University of Munich, Universitätsklinikum Heidelberg, University Hospital Aachen, Aristotle University of Thessaloniki, Foundation for Research and Technology – Hellas (FORTH), Hellenic Cancer Society, National and Kapodistrian University of Athens, National Hellenic Research Foundation (NHRF), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, IFOM Fondazione Istituto FIRC di Oncologia Molecolare, Istituto Europeo di Oncologia (IEO), Istituti Fisioterapici Ospitalieri – IRCCS Regina Elena, Italian National Research Council (CNR), Maggioli SpA, Neuromed IRCCS, Policlinico San Donato Research Hospital, Sapienza University of Rome, SYNLAB Italia, Università degli Studi di Bari Aldo Moro, University of Pisa, University of Latvia, Oslo Universitetssykehus HF, Amsterdam University Medical Center, EATRIS ERIC, Erasmus University Medical Center, Health-RI, Maastricht University, Radboud University Medical Center, The EGI Foundation, The Netherlands Cancer Institute (NKI), Gdańsk University of Technology, Łukasiewicz – PORT Polish Center for Technology Development, Medical University of Gdańsk, Champalimaud Foundation, Centro Hospitalar Universitário de Santo António, Liga Portuguesa Contra o Cancro – Núcleo Regional do Centro, Serviços Partilhados do Ministério da Saúde (SPMS), University of Coimbra, Andalusian Health Service (SAS), BAHIA Software, Barcelona Supercomputing Center (BSC), Centre for Genomic Regulation (CRG), CETIR Centre Medic SL, CIBER – Consorcio Centro de Investigación Biomédica en Red, Fundación Vicomtech, Fundación ISABIAL Alicante, Fundación de Investigación HM Hospitales, Fundación Pública Andaluza para la Gestión de la Investigación en Salud en Sevilla, Fundació Clínic per a la Recerca Biomèdica, Hospital Clínic de Barcelona, Instituto Aragonés de Ciencias de la Salud (IACS), Instituto de Salud Carlos III (ISCIII), Instituto Tecnológico de Informática (ITI), IQVIA, La Fe University and Polytechnic Hospital, MATICAL, Polytechnic University of Valencia, Quibim, S2 Grupo, Servicio Madrileño de Salud (SERMAS), Spanish National Research Council (CSIC), SYCAI Technologies, University of Barcelona, University of Valencia, Karolinska Institutet, Linköping University, National Bioinformatics Infrastructure Sweden (NBIS), Region Västerbotten, Umeå University, Vinnova.
Funding
EUCAIM is co-funded by the European Union Digital Europe programme under Grant Agreement No. 1011100633.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.